D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with NSCLC: Phase 1 Study Results.
Journal of thoracic oncology（2023）
关键词
Non-small cell lung cancer,KRAS G12C muta-tion,Phase 1 clinical trial,Small molecule agent
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要